Water-soluble powder for oral use

Ingredients (1 liter):

Doxycycline hyclate – 115 gr

Tylosin tartrate – 115 gr

Provides potentiating effect on mycoplasma and chlamydia

 Indications:

Poultry for medical and preventive purposes;

Pigs for medical purposes in the respiratory and gastrointestinal diseases of bacterial etiology, including pasteurellosis, mycoplasmosis, colibacillosis, salmonellosis, dysentery, enzootic pneumonia caused by Staphylococcus spp., Streptococcus spp., Bac. аntracis, Clostridium spp., Listeria, Actinomyces spp., Klebsiella spp., Shigella spp., Yersinia spp., Bordetella, Campylobacter, E. coli, Haemophylus, Pasteurella, Salmonella, Staphilococcus spp., Streptococcus spp., Treponema spp., а также Chlamydia, Mycoplasma и Rickettsia spp.

Dosage: orally with drinking water or mixed with feed at a dose of 500-1000 gr of product per 1000 l of water is equivalent to:

Elimination period:

 Complex decision in the treatment and prevention of bacterial diseases

 MACRODOX 200 is a water-soluble powder for oral use, which is composed of doxycycline hydrochloride and tylosin tartrate. This combination of two antibacterial components due to the fact that both belong to the same antibiotic group: “Fast-acting antibiotics with bacteriostatic action type, in which high concentrations of bactericidal effect.” The preparation has a broad spectrum of action and particularly effective in infections caused by Chlamydia, Mycoplasma and Rickettsia spp. The potentiating action of ingredients gives this effect. Synergies doxycycline and tylosin is a similar mechanism of action. Both components disrupt the synthesis of proteins of microbial cells. Thus doxycycline acts on receptors of 30 S ribosomal group blocking attachment amino acetyl tRNA to the acceptor spot to prevent the addition of new amino acids to a peptide chain and thus anticipates the protein synthesis. A mechanism of action is based on the tylosin 50 S ribosomal binding group of microbial cells, resulting in impaired the translocation of peptides and protein synthesis inhibition. This both-way mechanism at different parts of the RNA of microbial cells reinforces the antimicrobial effect of the medicine.

Registration number: 10-3-14.14-2413№ПВР-3-8.9/02468

To get the product, please send the request

Our contacts

Tel/fax +7 (4722) 58-57-42, 58-32-32

e-mail: sales@belfarma.com or client@belfarma.com